Advertisement Pharmaceutical Business review - Page 1200 of 5279 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 25, 2026

RQ Bio secures $115m to develop influenza antibody programme

UK-based RQ Bio has closed a £85.5m ($115m) Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.

RQ Bio CEO Mike Westby. Credit: RQ Bio/GlobeNewswire.